solute carrier family 27 member 1Genealiases: ACSVL5 · FATP · FATP-1 · FATP1
Q-omics provides the consensus-scored SLC27A1 profile across patient tissues and cancer cell-line models. SLC27A1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, SLC27A1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SLC27A1 protein abundance shows 40,396 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight DLBC, KIRC, and HNSC as cancer lineages where SLC27A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC27A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC27A1 survival associations across molecular data types. SLC27A1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC27A1 RNA expression–survival associations across cancer types. High SLC27A1 expression shows unfavorable associations in LGG, but favorable associations in DLBC, KIRC, HNSC, CESC and LIHC. The DLBC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for SLC27A1 RNA expression.
This table summarizes SLC27A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 13. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC27A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC27A1 shows lower tumor expression in LUAD, BRCA and LUSC and higher tumor expression in KIRC, COAD and KICH. The KIRC box plot shows higher SLC27A1 RNA expression in tumor versus normal tissue (log2 FC = +0.637, t-test p < 0.001).
This table shows molecular features associated with SLC27A1 in patient tissues and cancer cell lines. In patient samples, SLC27A1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC27A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
